» Articles » PMID: 39134872

The Role of MDM2 in Angiogenesis: Implications for Endothelial Tip Cell Formation

Overview
Publisher Springer
Specialties Biology
Cell Biology
Date 2024 Aug 12
PMID 39134872
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, we examined the role of MDM2 in the angiogenesis process and its potential association with the sprouting of endothelial tip cells. To address this, we performed hypoxia-treated gastric cancer cells (HGC-27) to quantitative RT-PCR and Western blot analysis to measure the levels of MDM2 and VEGF-A mRNA and protein expression. Subsequently, we employed siRNA to disrupt MDM2 expression, followed by hypoxia treatment. The expression levels of MDM2 and VEGF-A mRNA and protein were subsequently reassessed. Additionally, ELISA was utilized to quantify the secretion levels of VEGF-A in each experimental group. A conditioned medium derived from HGC-27 cells treated with different agents was employed to assess its influence on the formation of EA.hy926 endothelial tip cells, using various techniques including Transwell plates migration assays, wound healing experiments, vascular formation assays, scanning electron microscopy, and immunofluorescence staining. These findings demonstrated that the in vitro knockdown of MDM2 in the conditioned medium exhibited significant inhibitory effects on endothelial cell migration, wound healing, and vascular formation. Additionally, the intervention led to a reduction in the presence of CD34 tip cells and the formation of filopodia in endothelial cells, while partially restoring the integrity of tight junctions. Subsequent examination utilizing RNA-seq revealed that the suppression of MDM2 in HGC-27 cells resulted in the downregulation of the PI3K/AKT signaling pathway. Consequently, this downregulation led to an elevation in angiogenic effects induced by hypoxia.

References
1.
Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

2.
Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W . The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov. 2020; 6:53. PMC: 7305227. DOI: 10.1038/s41420-020-0287-y. View

3.
Carmeliet P, Jain R . Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249-57. DOI: 10.1038/35025220. View

4.
Cathcart J, Banach A, Liu A, Chen J, Goligorsky M, Cao J . Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression. Oncotarget. 2016; 7(38):61107-61120. PMC: 5308639. DOI: 10.18632/oncotarget.11243. View

5.
Chekhonin V, Shein S, Korchagina A, Gurina O . VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets. 2012; 13(4):423-43. DOI: 10.2174/15680096113139990074. View